148 citations
,
April 2009 in “Molecular Pharmaceutics” This study reports that three synthesized PSMA-targeted radioimaging agents demonstrated high affinity and specific localization to prostate cancer tumors in a mouse model, highlighting their potential for cancer detection and monitoring.
September 2010 in “European Urology Supplements” Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.
April 2022 in “Indian Journal of Forensic Medicine & Toxicology” This study found that PSA concentrations in peripheral blood are related to androgen levels, suggesting that PSA is a valuable marker for diagnosing hyperandrogenism in women.
8 citations
,
June 2016 in “Clinical Chemistry” This review discusses the expression of PSA in hormonally-regulated tissues and female malignancies, emphasizing its potential as a diagnostic biomarker and role in antidoping initiatives.
6 citations
,
January 2010 in “Neoplasma” In this study, researchers found that shorter CA repeats in the ERbeta gene are correlated with PSA expression, and PSA immunoexpression is associated with increased disease-free survival in breast cancer.
4 citations
,
March 2018 in “PloS one” This study found that among men over 70, certain genetic variants associated with skin pigmentation affect serum PSA levels, with implications for how sun sensitivity and exposure may influence prostate cancer risk.
3 citations
,
October 2011 in “QJM” This study found that 5α-reductase inhibitors significantly reduced low-grade prostate cancer incidence in men but nearly doubled the incidence of high-grade prostate cancers.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
September 2010 in “European Urology Supplements” PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
24 citations
,
June 2011 in “Andrologia” This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.
43 citations
,
August 2016 in “Scientific Reports” This animal study found that Cinnamomi cortex water extract reduced prostate weight and improved histological changes in a benign prostatic hyperplasia model, suggesting potential as a treatment.
9 citations
,
February 2022 in “Biomolecules” This review concludes that while many epidemiological studies suggest high alcohol intake is associated with an increased risk of prostate cancer, the evidence may be affected by confounding factors such as diet and lifestyle.
6 citations
,
May 2022 in “Research and reports in urology” This study found that Caesalpinia bonduc seed extracts significantly reduced prostate weight and improved prostate tissue morphology in Wistar rats with testosterone-induced benign prostatic hyperplasia.
20 citations
,
January 2017 in “Nutrition Research and Practice” In this study, corn silk extract treatment improved symptoms of testosterone-induced BPH by reducing specific mRNA expression and decreasing levels of 5α-R2, DHT, and PSA.
73 citations
,
November 2001 in “Journal of Investigative Dermatology Symposium Proceedings” This review examines histochemical and immunohistochemical markers to differentiate apocrine and eccrine sweat glands, highlighting their distinct markers, though it reports no new clinical findings.
April 2010 in “The Journal of Urology” This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.
101 citations
,
April 1994 in “Baillière's clinical endocrinology and metabolism” This review discusses the role of 5α-reductase enzymes in androgen action and related disorders, noting that their specific inhibitory drugs show promise for conditions like benign prostatic hypertrophy; it reports no new clinical results.
12 citations
,
January 2018 in “Journal of Drug Delivery Science and Technology” This study developed solid lipid nanoparticles for effective delivery of shRNA-encoding plasmids, showing reduced 5α-reductase levels in DU-145 cells without significant cytotoxicity.
December 2025 in “Naunyn-Schmiedeberg s Archives of Pharmacology” In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.
113 citations
,
July 2020 in “Communications biology” This review suggests that understanding the biological and molecular reasons for more severe COVID-19 in men, particularly those at risk for prostate cancer, could improve management of these patients, but reports no new results.
June 2023 in “SPIRE - Sciences Po Institutional REpository” This study suggests that extracellular vesicles from prostate cancer cells could aid in identifying tumor heterogeneity and serve as biomarkers, while also playing a role in SARS-CoV-2 infection in nasopharyngeal mucus.
This study reported that high cholesterol levels were linked to increased prostate cancer risk, while selenium supplementation affected gene expression, suggesting nutritional and clinical factors might influence prostate cancer risk and biology.
23 citations
,
January 2014 in “International Journal of Biological Sciences” This study found that African American men with prostate cancer have higher rates of somatic and germline androgen receptor mutations than Caucasian American men, which may contribute to ethnic differences in disease progression and outcomes.
51 citations
,
May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.
20 citations
,
March 2005 in “Current Medicinal Chemistry” This study reports that newly synthesized steroidal trienones exhibit higher 5α-reductase inhibitory activity than dienones in various biological models, suggesting potential use in treating androgen-dependent diseases.
May 2024 in “Scientific Reports” In this study, researchers examined androgen receptor activity in the adult mouse brain and found specific expression in key brain areas, which could inform understanding of cognitive side effects in humans undergoing androgen deprivation therapy for prostate cancer.
224 citations
,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” This study identifies SOX9 as a critical downstream effector of ERG in TMPRSS2:ERG fusion-positive prostate cancer, indicating its role in tumor invasion and growth.
January 2025 in “Applied Sciences” This review examines sulforaphane's interactions with hormone-mediated health conditions, focusing on gender-specific health issues, but reports no new original research findings.
45 citations
,
April 2018 in “Nature Reviews Urology” This review discusses the molecular mechanisms of masculinization involving androgen signaling and their roles in male embryonic development and conditions like hypospadias and prostate cancer, and reports no clinical results.